28 analysts have shared their evaluations of Eli Lilly (NYSE:LLY) during the recent three months, expressing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 9 | 19 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 3 | 2 | 0 | 0 | 0 |
2M Ago | 3 | 6 | 0 | 0 | 0 |
3M Ago | 3 | 10 | 0 | 0 | 0 |
Analysts have set 12-month price targets for Eli Lilly, revealing an average target of $964.46, a high estimate of $1125.00, and a low estimate of $884.00. Observing a 5.33% increase, the current average has risen from the previous average price target of $915.68.
![1725912015_0.png](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240910/43396764-0-fa333edd2519a670db703c4e6e4542cb.png/big)
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Eli Lilly among financial experts is...
Login or create a forever free account to read this news
Sign up/Log in